Helen Susilowati, Helen
Stem cell Research and Development Center, Airlangga University, Surabaya-Indonesia

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

THE CHANGING CLINICAL PERFORMANCE OF DENGUE VIRUS INFECTION IN THE YEAR 2009 Soegijanto, Soegeng; Susilowati, Helen; Mulyanto, Kris Cahyo; Hendrianto, Eryk; Yamanaka, Atushi
Indonesian Journal of Tropical and Infectious Disease Vol 3, No 1 (2012)
Publisher : Institute of Topical Disease

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (173.129 KB)

Abstract

Background: Dengue (DEN) virus, the most important arthropod-borne human pathogen, represents a serious public health threat. DEN virus is transmitted to humans by the bite of the domestic mosquito, Aedes aegypti, and circulates in nature as four distinct serological types DEN-1 to 4). The aim of Study: To identify Dengue Virus Serotype I which showed mild clinical performance in fiveyears before and afterward showed severe clinical performance. Material and Method: Prospective and analytic observational study had been done in Dr. Soetomo Hospital and the ethical clearance was conduct on January 01, 2009. The population of this research is all cases of dengue virus infection. Diagnosis were done based on WHO 1997. All of these cases were examined for IgM & IgG anti Dengue Virus and then were followed by PCR examination to identify Dengue Virus serotype. Result and Discussion: DEN 2 was predominant virus serotype with produced a spectrum clinical illness from asymptomatic, mild illness to classic dengue fever (DF) to the most severe form of illness (DHF). But DEN 1 usually showed mild illness. Helen at al (2009–2010) epidemiologic study of Dengue Virus Infection in Health Centre Surabaya and Mother and Child Health Soerya Sidoarjo found many cases of Dengue Hemorrhagic Feverwere caused by DEN 1 Genotype IV. Amor (2009) study in Dr. Soetomo Hospital found DEN 1 showed severe clinical performance of primary Dengue Virus Infection as Dengue Shock Syndrome two cases and one unusual case.Conclusion: The epidemiologic study of Dengue Virus Infection in Surabaya and Sidoarjo; in the year 2009 found changing predominant Dengue Virus Serotype from Dengue Virus II to Dengue Virus 1 Genotype IV which showed a severe clinical performance coincident with primary infection.
Chondrogenic Differentiation Capacity of Human Umbilical Cord Mesenchymal Stem Cells with Platelet Rich Fibrin Scaffold in Cartilage Regeneration (In Vitro Study) Sumarta, Ni Putu Mira; D, Coen Pramono; Hendrianto, Eryk; Susilowati, Helen; Karsari, Deya; Rantam, Fedik A.
BALI MEDICAL JOURNAL Vol 5 No 3 (2016)
Publisher : BALI MEDICAL JOURNAL

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (541.428 KB)

Abstract

Background: Human umbilical cord mesenchymal stem cell is a promising source of allogenous MSC with great chondrogenic differentiation capacity. Meanwhile, platelet rich fibrin (PRF) is a natural fibrin matrix, rich in growth factors, forming a smooth and flexible fibrin network, supporting cytokines and cell migration, thus can be used as a scaffold that facilitate the differentiation of MSC. However, the differential capability of MSC cultured in PRF was still poorly understood. Method: We studied in vitro differentiation potential of MSC cultured in PRF by evaluating several markers such as FGF 18, Sox 9, type II collagen, aggrecan in 3 different culture medium. Result: The result showed that there was positive expression of FGF 18, Sox 9, type II collagen, aggrecan in all medium of in vitro culture. Conclusion: MSC cultured from human umbilical cord had the capacity of chondrogenic differentiation and able to produce cartilage extracellular matrix in vitro which means that hUCMSC is a potential allogeneic MSC for cartilage regeneration.
THE CHANGING CLINICAL PERFORMANCE OF DENGUE VIRUS INFECTION IN THE YEAR 2009 Soegijanto, Soegeng; Susilowati, Helen; Mulyanto, Kris Cahyo; Hendrianto, Eryk; Yamanaka, Atushi
Indonesian Journal of Tropical and Infectious Disease Vol. 3 No. 1 (2012)
Publisher : Institute of Topical Disease Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (173.129 KB) | DOI: 10.20473/ijtid.v3i1.193

Abstract

Background: Dengue (DEN) virus, the most important arthropod-borne human pathogen, represents a serious public health threat. DEN virus is transmitted to humans by the bite of the domestic mosquito, Aedes aegypti, and circulates in nature as four distinct serological types DEN-1 to 4). The aim of Study: To identify Dengue Virus Serotype I which showed mild clinical performance in fiveyears before and afterward showed severe clinical performance. Material and Method: Prospective and analytic observational study had been done in Dr. Soetomo Hospital and the ethical clearance was conduct on January 01, 2009. The population of this research is all cases of dengue virus infection. Diagnosis were done based on WHO 1997. All of these cases were examined for IgM & IgG anti Dengue Virus and then were followed by PCR examination to identify Dengue Virus serotype. Result and Discussion: DEN 2 was predominant virus serotype with produced a spectrum clinical illness from asymptomatic, mild illness to classic dengue fever (DF) to the most severe form of illness (DHF). But DEN 1 usually showed mild illness. Helen at al (2009–2010) epidemiologic study of Dengue Virus Infection in Health Centre Surabaya and Mother and Child Health Soerya Sidoarjo found many cases of Dengue Hemorrhagic Feverwere caused by DEN 1 Genotype IV. Amor (2009) study in Dr. Soetomo Hospital found DEN 1 showed severe clinical performance of primary Dengue Virus Infection as Dengue Shock Syndrome two cases and one unusual case.Conclusion: The epidemiologic study of Dengue Virus Infection in Surabaya and Sidoarjo; in the year 2009 found changing predominant Dengue Virus Serotype from Dengue Virus II to Dengue Virus 1 Genotype IV which showed a severe clinical performance coincident with primary infection.
Epidermal Growth Factor Promotes E6 and CCL-81 Vero Cells Proliferation Under Serum-Free Condition Delaiah, Diena; Aswin, Ahmad; Susilowati, Helen; Wijaya, Andi Yasmin; Maulana, Firdausy Kurnia; Diyantoro, Diyantoro; Rodprasert, Watchareewan; Puspitasari, Yulianna; Dhamayanti, Yeni; Kuncorojakti, Suryo
Jurnal Medik Veteriner Vol. 7 No. 1 (2024): April
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jmv.vol7.iss1.2024.1-6

Abstract

Vero cell culture as a platform for producing viral vaccines is an established and standardized process in vaccine manufacture. Generally, Vero cell culture requires media as a source of nutrition with serum supplementation to provide growth factors. However, the serum has several disadvantages including batch to batch variation and adventitious agent. Therefore, chemically defined serum-free media (SFM) are formulated by using standardized growth factors. Epidermal Growth Factor (EGF) is one of growth factors that showed adequate mitogenic support in serum-free medium system, especially in Vero cells. In this study, SFM-EGF media was compared with serum supplementation media, namely MEM 10% and MEM 5% FBS supplementation. The cell morphology was observed using an inverted microscope and their proliferation was evaluated using a MTT colorimetric-based assay. Vero E6 and Vero CCL-81 cells morphology did not show any morphological changes. Vero E6 and Vero CCL-81 proliferation in SFM-EGF media on day one to four did not show a significant difference compared to MEM 10% or MEM 5% serum supplementation media. However, the OD values of both Vero E6 and Vero CCL-81 cells given SFM-EGF media produced an average value below MEM 10% but higher than MEM 5% FBS supplementation. As such, this study proved that utilizing SFM-EGF could support the proliferation of Vero E6 and Vero CCL-81 cells.
Analysis of morphology, cytotoxicity, and water content characteristics of freeze-dried amnion membrane from human and bovine Suroto, Heri; Pratamanugroho, Ilham; Prajasari, Tabita; Susilowati, Helen; Khang, Gilson
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.991

Abstract

Placenta tissue has biological advantages, including anti-inflammatory, anti-bacterial, anti-fibrotic formation, and immunomodulatory properties. The amnion membrane (AM) is an inner side membrane of the placenta that faces the fetus. The main sources of amnion are humans and animals, with bovine being one of the significant sources. The aim of this study was to analyze the morphology, cytotoxicity, and water content characteristic of freeze‑dried amnion membrane (FD‑AM) from humans and bovines to measure the safety and compatibility of bovine FD-AM as an alternative to human FD-AM. This study is an observational cross-sectional study. Samples were divided into two groups: human FD-AM and bovine FD-AM groups. Both groups were examined for morphology characteristics by scanning electron microscopy (SEM), cytotoxicity by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) analysis, and water content by drying through moisture analyzer device. The morphology characteristics of bovine FD-AM and human FD-AM, as observed through SEM, showed similar results of a smooth, flat surface with no cavity and were well dehydrated. MTT assay analysis on both groups demonstrated cytocompatibility with cell viability exceeding 70% in the control group. However, human FD-AM showed a higher number of viable cells (0.19±0.01) compared to bovine FD-AM (0.12±0.03), with a statistically significant difference (p<0.05). The water content analysis revealed that both groups met the standard, with levels below 10%. While bovine FD-AM (7.19±0.45%) had slightly higher water content than human FD-AM (6.79±1.0%), the difference was not significant (p>0.05). Both human FD-AM and bovine FD-AM showed good results in morphology, cytotoxicity, and water content characteristics and compatibility. In conclusion, bovine FD-AM might be considered as an alternative to human FD-AM.
Evaluation and Its Impact of SARS-CoV-2 Inactivated Vaccine Candidate in K18-hACE2 Mice A'la, Rofiqul; Rantam, Fedik Abdul; Wijaya, Andi Yasmin; Susilowati, Helen; Kuncorojakti, Suryo; Diyantoro, Diyantoro; Aswin, Ahmad; Rahmahani, Jola; Suwanti, Lucia Tri; Lukiswanto, Bambang Sektiari; Yudaniayanti, Ira Sari; Setiawan, Boedi
Jurnal Medik Veteriner Vol. 8 No. 1 (2025): April
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jmv.vol8.iss1.2025.54-62

Abstract

The COVID-19 pandemic caused by SARS-CoV-2 requires effective vaccines to be developed. This study aimed to assess the impact of a SARS-CoV-2 inactivated vaccine candidate in k18-hACE2 mice by monitoring their body weight, immune activation, and inflammatory cytokines including IL-4, IL-6, TNF-α, and IFN-γ. The study utilized k18-hACE2 mice expressing the human angiotensin-converting enzyme 2 (hACE2) receptor. The mice were administered the inactivated vaccine candidate compared with sham and vehicle. Body weight was monitored, and serum samples were collected to measure IL-4, IL-6, TNF-α, and IFN-γ levels using ELISA. Data were evaluated using SPSS statistical analysis software. The administration of the SARS-CoV-2 inactivated vaccine candidate in k18-hACE2 mice did not result in significant changes in body weight compared to the control group. Furthermore, the levels of IL-4, IL-6, TNF-α, and IFN-γ were significantly reduced in the vaccinated mice compared to the control group, suggesting a dampening effect on the inflammatory response. This study demonstrates that the SARS-CoV-2 inactivated vaccine candidate has a minimal impact on the body weight of k18-hACE2 mice. Nevertheless, it successfully regulates the levels of IL-4, IL-6, TNF-α, and IFN-γ, suggesting its safety and beneficial impact. These findings contribute to understanding the vaccine's efficacy and safety profile in vaccine development.